CICC Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
I'm PortAI, I can summarize articles.
In a report released yesterday, from CICC maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$45.00. The company’s shares closed last Monday at HK$40.02.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Currently, the analyst consensus on Wuxi Biologics (Cayman) is a Strong Buy with an average price target of HK$40.23.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments